Gene: FEM1A
Official Full Name: fem-1 homolog Aprovided by HGNC
Gene Summary: Enables EP4 subtype prostaglandin E2 receptor binding activity and ubiquitin-like ligase-substrate adaptor activity. Involved in negative regulation of inflammatory response and ubiquitin-dependent protein catabolic process via the C-end degron rule pathway. Part of Cul2-RING ubiquitin ligase complex. Is active in mitochondrion. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO17637 | FEM1A Knockout cell line (HeLa) | Human | FEM1A | 1:3~1:6 | Negative | Online Inquiry |
KO17638 | FEM1A Knockout cell line (HCT 116) | Human | FEM1A | 1:2~1:4 | Negative | Online Inquiry |
KO17639 | FEM1A Knockout cell line (HEK293) | Human | FEM1A | 1:3~1:6 | Negative | Online Inquiry |
FEM1A Gene Knockout Cell Lines are specialized cell models that have been engineered to lack the functional FEM1A gene, which is involved in various cellular processes including protein ubiquitination and regulation of the cell cycle. By selectively knocking out this gene, researchers can elucidate the role of FEM1A in cellular physiology and its implications in diseases such as cancer. These cell lines serve as powerful tools to investigate the impact of FEM1A deficiency on cellular behavior, signaling pathways, and gene expression profiles.
The primary function of FEM1A Gene Knockout Cell Lines is to provide a controlled environment for dissecting the phenotypic consequences of the absence of the FEM1A protein. By utilizing CRISPR/Cas9 technology, these cell lines enable precise gene editing, ensuring that the knockout is specific and efficient. Researchers can leverage these models to study mechanisms of drug resistance, apoptosis, and other critical biological processes, facilitating a deeper understanding of disease mechanisms at the molecular level.
The scientific importance of these cell lines cannot be overstated. In both research and clinical settings, they are invaluable for drug discovery, biomarker identification, and the development of targeted therapies. Understanding the role of FEM1A in disease pathways can lead to innovative treatment strategies, particularly in oncology.
Compared to other gene knockout systems, FEM1A Gene Knockout Cell Lines offer the advantage of established characterization and reliability, significantly reducing variability and increasing reproducibility in experimental outcomes. Furthermore, these cell lines are compatible with high-throughput screening methods, making them ideal for studies aiming to identify new therapeutic compounds.
For researchers and clinicians dedicated to advancing knowledge in genetics and molecular biology, the availability of FEM1A Gene Knockout Cell Lines represents a significant opportunity to propel their work. With their utility in elucidating pathways that govern critical cellular functions, these models contribute to the overarching quest for targeted therapies and personalized medicine.
Our company is committed to delivering high-quality biological products that empower researchers worldwide. With a focus on precision and innovation, we provide tools that enhance scientific discovery, making us a trusted partner in the life sciences community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.